Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

991
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
991
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

904
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
904
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

1.1K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.1K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

784
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
784
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early treatment of Atrial fibrillation for Stroke prevention Trial in acute STROKE (EAST-STROKE): protocol for an international investigator-initiated, prospective, randomised, open, blinded endpoint assessment (PROBE) interventional multi-centre trial.

European stroke journal·2026
Same author

Validation of the SMART-REACH model after stroke and the effect of colchicine by atherosclerotic cardiovascular disease risk category: a secondary analysis of the CONVINCE randomised clinical trial.

European stroke journal·2026
Same author

Implementing suicide prevention in the workplace.

The lancet. Psychiatry·2026
Same author

Status on stroke and stroke care in Europe 2023: Stroke Service Tracker 2023 data based on 1,460,360 strokes in 47 European nations.

European stroke journal·2026
Same author

Recovery-induced tipping in Stommel's kicked ocean box model.

PloS one·2026
Same author

Stroke Action Plan for Europe 2018-2030 (SAP-E): mid-term review and update.

European stroke journal·2026
Same journal

Oral health in palliative care: bridging guidance and reality.

British journal of community nursing·2026
Same journal

Living alone with diabetes: a phenomenological study.

British journal of community nursing·2026
Same journal

Navigating the complexities of alcohol use in patient care.

British journal of community nursing·2026
Same journal

Frailty and falls in older adults: risk assessment and management for community nurses.

British journal of community nursing·2026
Same journal

Hardiness and care-related stress in Iranian Alzheimer's caregivers: a cross-sectional study.

British journal of community nursing·2026
Same journal

Incontinence, health disparities and healthcare complexities.

British journal of community nursing·2026
See all related articles

Related Experiment Video

Updated: Mar 8, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K

Achieving effective glycaemic control using an insulin micro-pump.

Peter Kelly1

  • 1Diabetes Specialist Nurse, Diabetes Centre, Derriford Hospital, Plymouth.

British Journal of Community Nursing
|February 7, 2017
PubMed
Summary
This summary is machine-generated.

A new insulin patch pump improved blood glucose control for type 1 diabetes mellitus (T1DM) patients, reducing variability and enhancing their quality of life. This technology offers better diabetes management and patient empowerment.

Keywords:
blood glucose variabilityconcordanceinsulin delivery systems

More Related Videos

A Multi-Parametric Islet Perifusion System within a Microfluidic Perifusion Device
07:55

A Multi-Parametric Islet Perifusion System within a Microfluidic Perifusion Device

Published on: January 26, 2010

12.4K
Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

11.0K

Related Experiment Videos

Last Updated: Mar 8, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K
A Multi-Parametric Islet Perifusion System within a Microfluidic Perifusion Device
07:55

A Multi-Parametric Islet Perifusion System within a Microfluidic Perifusion Device

Published on: January 26, 2010

12.4K
Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

11.0K

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Medical Devices

Background:

  • Type 1 diabetes mellitus (T1DM) management involves complex insulin regimens.
  • Poor blood glucose control leads to hypo/hyperglycaemic episodes and long-term microvascular complications.
  • Insulin delivery methods impact treatment adherence and patient quality of life.

Purpose of the Study:

  • To evaluate the effectiveness of a novel insulin patch pump system.
  • To assess the impact of the new patch pump on blood glucose variability in T1DM patients.
  • To determine the effect of improved glycemic control on patients' quality of life.

Main Methods:

  • A cohort of T1DM patients utilized a new insulin patch pump system.
  • Continuous subcutaneous insulin infusion (CSII) was delivered via the patch pump.
  • Blood glucose variability and quality of life metrics were monitored.

Main Results:

  • The new patch pump demonstrated an improvement in blood glucose variability.
  • Patients experienced enhanced quality of life following the implementation of the new device.
  • The patch pump facilitated better insulin delivery, monitoring, and adjustment.

Conclusions:

  • The novel insulin patch pump is an effective tool for managing T1DM.
  • Improved blood glucose control using this device positively impacts patient quality of life.
  • Patch pump technology offers enhanced diabetes management and patient autonomy.